Welcome to our dedicated page for I-Mab SEC filings (Ticker: IMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IMAB SEC filings page provides access to the regulatory documents filed by I-Mab, now operating under the name NovaBridge Biosciences, with the U.S. Securities and Exchange Commission. As a foreign private issuer listed on the Nasdaq Global Market, the company reports primarily on Form 20-F for annual disclosures and Form 6-K for interim updates and material events. These filings give investors detailed insight into the company’s financial condition, strategic transactions, and progress as it transitions into a global biotech platform.
Recent Form 6-K reports include management’s discussion and analysis and unaudited condensed consolidated financial statements for the six months ended June 30, 2025, as well as business model updates describing the shift to a hub-and-spoke structure and the creation of subsidiaries such as Visara, Inc. Other 6-K filings document the divestiture of Greater China assets and business operations, the acquisition of Bridge Health Biotech Co., Ltd., and agreements related to VIS-101 with AffaMed Therapeutics and AskGene Pharma, Inc.
Filings also record corporate actions such as the shareholder-approved change of the company’s English name from I-Mab to NovaBridge Biosciences and the corresponding change of the Nasdaq ticker symbol from IMAB to NBP. Extraordinary general meeting results, amendments to the memorandum and articles of association, and director and executive appointments are captured in these reports. In addition, certain 6-Ks incorporate press releases and scientific posters or presentations on givastomig’s Phase 1 monotherapy and combination data as exhibits.
On Stock Titan, this page surfaces IMAB-related SEC submissions as they become available from EDGAR and pairs them with AI-powered summaries that explain the key points in clear language. Users can quickly scan business model changes, licensing and collaboration agreements, financing transactions, and clinical development disclosures without reading every line of each filing, while still having direct access to the underlying documents for deeper review.
I-MAB has announced positive Phase 1b dose escalation data for their drug candidate Givastomig in combination with immunochemotherapy for first-line treatment of gastric cancers. The results were presented at the ESMO GI 2025 conference.
This Form 6-K, filed by the Maryland-based biopharmaceutical company, includes an exhibit (99.1) containing the press release detailing the clinical trial outcomes. The filing was signed by Joseph Skelton, the company's Chief Financial Officer.
The filing indicates that I-MAB continues to file annual reports under Form 20-F as a foreign private issuer. This development represents a significant milestone in I-MAB's oncology pipeline, particularly in the gastric cancer treatment landscape.